Cargando…

BRAF Inhibitors in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: The identification of BRAF mutations in 1.5–3.5% of NSCLC patients represents a step forward towards new targeted agents for tackling NSCLC. The positive results and favourable safety profile observed with the combination of dabrafenib and trametinib for the treatment of BRAF V600E m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sforza, Vincenzo, Palumbo, Giuliano, Cascetta, Priscilla, Carillio, Guido, Manzo, Anna, Montanino, Agnese, Sandomenico, Claudia, Costanzo, Raffaele, Esposito, Giovanna, Laudato, Francesca, Damiano, Simona, Forte, Cira Antonietta, Frosini, Giulia, Farese, Stefano, Piccirillo, Maria Carmela, Pascarella, Giacomo, Normanno, Nicola, Morabito, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562258/ https://www.ncbi.nlm.nih.gov/pubmed/36230797 http://dx.doi.org/10.3390/cancers14194863

Ejemplares similares

Angiogenesis Inhibitors in Small Cell Lung Cancer
por: Montanino, Agnese, et al.
Publicado: (2021)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Immunotherapy in Small Cell Lung Cancer
por: Esposito, Giovanna, et al.
Publicado: (2020)

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
por: Palumbo, Giuliano, et al.
Publicado: (2020)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology
por: Pascarella, Giacomo, et al.
Publicado: (2019)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Multimodal approaches and tailored therapies for pain management: the trolley analgesic model
por: Cuomo, Arturo, et al.
Publicado: (2019)

The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain
por: Bimonte, Sabrina, et al.
Publicado: (2021)

An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection
por: Bimonte, Sabrina, et al.
Publicado: (2021)

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
por: Pasquale, Raffaella, et al.
Publicado: (2020)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Advantages and issues of concern regarding approaches to peripheral nerve block for total hip arthroplasty
por: Crisci, Marco, et al.
Publicado: (2021)

Could the perioperative use of opioids influence cancer outcomes after surgery? A scoping review protocol
por: Cascella, Marco, et al.
Publicado: (2022)

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
por: Celesia, Adriana, et al.
Publicado: (2023)

Transportation systems analysis: models and applications
por: Cascetta, Ennio
Publicado: (2009)

Transportation systems engineering theory and methods
por: Cascetta, Ennio
Publicado: (2001)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Unusual metastases of melanoma
por: Carillio, Guido, et al.
Publicado: (2018)

Promising Role of Circulating Tumor Cells in the Management of SCLC
por: De Luca, Antonella, et al.
Publicado: (2021)

S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas
por: Mehdi, A., et al.
Publicado: (2023)

The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
por: Celesia, Adriana, et al.
Publicado: (2022)

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a (V600E)BRAF inhibitor): a case report
por: Simeone, Ester, et al.
Publicado: (2012)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
por: Miele, Evelina, et al.
Publicado: (2020)

Multiple effectiveness aspects of tapentadol for moderate–severe cancer-pain treatment: an observational prospective study
por: Cascella, M, et al.
Publicado: (2018)

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
por: Gelsomino, Francesco, et al.
Publicado: (2021)

COVID-Pain: Acute and Late-Onset Painful Clinical Manifestations in COVID-19 – Molecular Mechanisms and Research Perspectives
por: Cascella, Marco, et al.
Publicado: (2021)

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2016)

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
por: Gargiulo, Piera, et al.
Publicado: (2021)

Machine Learning-Based Segmentation of the Thoracic Aorta with Congenital Valve Disease Using MRI
por: Sundström, Elias, et al.
Publicado: (2023)

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
por: Esposito Abate, Riziero, et al.
Publicado: (2019)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring
por: Barchiesi, Vittoria, et al.
Publicado: (2021)

KRAS and BRAF mutational status in colon cancer from Albanian patients
por: Martinetti, Daniela, et al.
Publicado: (2014)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l55gje9krcd7o73nsi0qg9u8q8